Wedding Five Prime Therapeutics’ experimental CSF-1 receptor inhibitor cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved a bust in pancreatic cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,